Key result
Trimetazidine improves LVEF by ~4 percentage points and lowers BNP in dilated cardiomyopathy.
Why the study?
Altered substrate metabolism plays an important role in the pathophysiology of heart failure, and optimizing myocardial energy metabolism with metabolic modulators like trimetazidine may allow more efficacious energy production in dilated cardiomyopathy.
Does trimetazidine improve functional status, BNP, and echocardiographic parameters in patients with dilated cardiomyopathy?
RCT (n=100)
1:1
No
Does trimetazidine improve functional status, BNP, and echocardiographic parameters in patients with dilated cardiomyopathy?
Trimetazidine added to conventional therapy significantly improves functional capacity, left ventricular ejection fraction, and BNP levels in patients with dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports adjunctive trimetazidine in dilated cardiomyopathy; extends RCT evidence for metabolic modulation in HFrEF.
Altered substrate metabolism plays an important role in pathophysiology of heart failure (HF). Optimization of myocardial energy metabolism with metabolic modulators like trimetazidine (TMZ) allows more efficacious energy production.
No takes yet. Share an insight, caveat, or question.
Kapoor et al. (2015) conducted an RCT in Dilated cardiomyopathy (n=100). Trimetazidine vs. Conventional therapy was evaluated on Left ventricular ejection fraction (LVEF) at 3 months (p=0.0001). Trimetazidine improved LVEF, functional class, and BNP levels at 3 months in dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: